Axel Finckh is an expert in Rheumatology at University Hospital of Geneva (Switzerland). As of October 2026, ScienceLeadR ranks Axel Finckh in the top 1% of experts worldwide for Arthritis and Autoimmune Diseases. Axel Finckh has authored 361 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 1,314 (community average: 125). How the SLR is computed.

LeadR Profile

Axel Finckh University Hospital of Geneva Switzerland
1 314 ScienceLeadR Reputation 1314
Network Map

Rheumatology

Subspecialties: Pharmacy - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026

Source: PubMed

University Hospital of Geneva

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 361

Citations

Citations: 19 827 1st author: 47 Last author: 85 Unique author: 12


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cell-type specific analyses in blood and gut identify cis-eQTL matching 140 IBD risk loci and entrectinib as repurposing candidate.
PMID 42768013 — cells, genes, blood, pharmaceutical preparations, inflammatory bowel diseases
Nat Commun20260
Risk-benefit considerations for antirheumatic drug use in pregnancy, breastfeeding, and male preconception: expert perspectives.
PMID 42539978 — pregnancy, safety, colchicine, pharmaceutical preparations, antirheumatic agents, breast feeding, therapeutics
EULAR Rheumatol Open20260
Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry.
PMID 42336611 — registries, arthritis, rheumatic diseases, rituximab, abatacept, arthritis, rheumatoid, therapeutics
RMD Open20260
Persistence and Effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries.
PMID 42334951 — registries, arthritis, rheumatic diseases, arthritis, rheumatoid, therapeutics
Rheumatology (Oxford)20260
A pharmacist-led intervention to promote the uptake of an infliximab biosimilar by patients and physicians in a university hospital rheumatology unit.
PMID 42325206 — rheumatology, rheumatologists, pharmacists, physicians, disulfiram, education, universities, infliximab, biosimilar pharmaceuticals
Eur J Hosp Pharm20250

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2
Phase 1/Phase 2 1
Phase 2 1
Phase 4 1

By status:

Completed 5

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

LeadR Networks

Main global connection map